** Shares of Stoke Therapeutics STOK.O rise 12.6% to $12.88
** The biotech says it has received U.S. FDA's "breakthrough therapy designation" for zorevunersen, its experimental drug for epileptic disorder Dravet Syndrome
** The FDA's tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need
** Breakthrough designation seems appropriate given disease modifying potential in a field of symptomatic treatments, brokerage BTIG says
** If approved, the drug could become the first disease modifying treatment for the disease
** Including session's moves, stock up 143.54% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。